Cytosorbents Corp Stock OTC Bulletin Board
Stocks
CTSO
US23283X1072
Advanced Medical Equipment & Technology
| Market Cap | 23.7M 20.52M 19.13M 17.6M 33.2M 2.25B 33.6M 225M 88.2M 1.13B 89M 87.04M 3.74B | P/E 2026 * |
-2.08x | P/E 2027 * | 12.8x |
|---|---|---|---|---|---|
| Enterprise Value | 23.7M 20.52M 19.13M 17.6M 33.2M 2.25B 33.6M 225M 88.2M 1.13B 89M 87.04M 3.74B | EV / Sales 2026 * |
0.62x | EV / Sales 2027 * | 0.5x |
| Free-Float |
84.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytosorbents Corp
| 1 day | -6.91% |
| Manager | Title | Age | Since |
|---|---|---|---|
Phillip Chan
CEO | Chief Executive Officer | 55 | 2008-07-23 |
Peter Mariani
DFI | Director of Finance/CFO | 62 | 2024-08-13 |
Vincent Capponi
PSD | President | 68 | 2020-04-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Edward Jones
BRD | Director/Board Member | 77 | 2011-07-24 |
Phillip Chan
BRD | Director/Board Member | 55 | 2008-12-31 |
Alan Sobel
BRD | Director/Board Member | 65 | 2014-11-12 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.91% | -.--% | - | - | 23.7M | |
| +2.32% | +0.25% | +23.85% | +5.32% | 209B | |
| +2.51% | +0.31% | +1.11% | -21.63% | 137B | |
| +1.88% | +3.70% | -22.38% | +21.30% | 130B | |
| -2.75% | +3.65% | -55.30% | -5.88% | 71.14B | |
| -0.70% | +6.32% | +11.09% | +11.84% | 51.59B | |
| +0.62% | +9.24% | -15.14% | -20.39% | 49.99B | |
| +1.37% | +0.41% | +22.88% | +11.73% | 39.31B | |
| +0.99% | +4.19% | +40.06% | +37.98% | 38.89B | |
| +0.40% | +7.21% | -23.13% | +24.98% | 32.19B | |
| Average | -0.03% | +3.19% | -1.88% | +7.25% | 84.33B | |
| Weighted average by Cap. | +1.29% | +1.42% | -0.24% | +3.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.26M 33.13M 30.88M 28.42M 53.61M 3.64B 54.26M 363M 142M 1.82B 144M 141M 6.03B | 47.12M 40.8M 38.03M 35M 66.02M 4.48B 66.82M 447M 175M 2.24B 177M 173M 7.43B |
| Net income | -11.74M -10.16M -9.48M -8.72M -16.45M -1.12B -16.65M -111M -43.7M -558M -44.09M -43.12M -1.85B | 2.37M 2.05M 1.92M 1.76M 3.32M 226M 3.36M 22.5M 8.83M 113M 8.91M 8.72M 374M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
